Clinigen to acquire Idis for £225 million

24 April 2015

Specialty pharma firm Clinigen Group (AIM: CLIN) has agreed to acquire fellow UK-based Idis Group creating the market leader in the ethical unlicensed supply of medicines. Idis is being acquired for an enterprise value of £225 million ($337 million).

Highlights

The global ethical unlicensed supply market represents a significant growth opportunity, estimated in excess of $5 billion and is under-penetrated.
On completion, Clinigen, as the market leader, will be well placed to shape and define this fast growing and critically important market.
Idis is a strong brand, with a 25 year history, and supplies unlicensed medicines predominantly on an exclusive basis through managed access programs and on-demand through its general access division.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK